These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33481252)

  • 1. Use and outcome of empiric echinocandins in critically ill patients.
    Ylipalosaari P; Ala-Kokko TI; Koskenkari J; Laurila JJ; Ämmälä S; Syrjälä H
    Acta Anaesthesiol Scand; 2021 Aug; 65(7):944-951. PubMed ID: 33481252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
    Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
    Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice.
    Chandwani S; Wentworth C; Burke TA; Patterson TF
    Curr Med Res Opin; 2009 Feb; 25(2):385-93. PubMed ID: 19192983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic changes in surgical intensive care unit patients undergoing echinocandin treatment.
    Koch C; Schneck E; Arens C; Markmann M; Sander M; Henrich M; Weigand MA; Lichtenstern C
    Int J Clin Pharm; 2020 Feb; 42(1):72-79. PubMed ID: 31748967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance.
    Gioia F; Gomez-Lopez A; Alvarez ME; Gomez-García de la Pedrosa E; Martín-Davila P; Cuenca-Estrella M; Moreno S; Fortun J
    Int J Infect Dis; 2020 Dec; 101():24-28. PubMed ID: 32937195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.
    Heimann SM; Cornely OA; Wisplinghoff H; Kochanek M; Stippel D; Padosch SA; Langebartels G; Reuter H; Reiner M; Vierzig A; Seifert H; Vehreschild MJ; Glossmann J; Franke B; Vehreschild JJ
    Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):331-8. PubMed ID: 25213718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.
    Liu X; Liu D; Pan Y; Li Y
    J Clin Pharm Ther; 2020 Dec; 45(6):1207-1217. PubMed ID: 32672361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of first-line therapies for the treatment of candidemia in ICU patients: A propensity score analysis.
    Bienvenu AL; Pradat P; Guerin C; Aubrun F; Fellahi JL; Friggeri A; Guichon C; Hernu R; Menotti J; Monard C; Paulus S; Rimmele T; Piriou V; Chidiac C; Argaud L; Leboucher G
    Int J Infect Dis; 2020 Apr; 93():15-21. PubMed ID: 31982622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of Anidulafungin in Critically Ill Intensive Care Unit Patients with Suspected or Proven Invasive Fungal Infections.
    Brüggemann RJ; Middel-Baars V; de Lange DW; Colbers A; Girbes AR; Pickkers P; Swart EL
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Echinocandins: Their role in the management of
    Swaminathan S; Kamat S; Pinto NA
    Indian J Med Microbiol; 2018; 36(1):87-92. PubMed ID: 29735833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication.
    Vekeman F; Weiss L; Aram J; Ionescu-Ittu R; Moosavi S; Xiao Y; Cheng WY; Bhak RH; Tawadrous M; Capparella MR; Montravers P; Duh MS
    BMC Infect Dis; 2018 Aug; 18(1):438. PubMed ID: 30157797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics of the three echinocandins in ICU patients.
    Mainas E; Apostolopoulou O; Siopi M; Apostolidi S; Neroutsos E; Mirfendereski H; Marchand S; Couet W; Dokoumetzidis A; Valsami G; Sambatakou H; Dimopoulos G; Meletiadis J
    J Antimicrob Chemother; 2020 Oct; 75(10):2969-2976. PubMed ID: 32696036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Patients treated with micafungin during their stay in intensive care unit].
    Álvarez-Lerma F; Grau S; López C; Jiménez JD; Trasmonte MV; Nieto M; Parra G; Herrero E;
    Med Intensiva; 2015 Nov; 39(8):467-76. PubMed ID: 25798955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
    Timsit JF; Azoulay E; Schwebel C; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Argaud L; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Maubon D; Jullien V; Wolff M;
    JAMA; 2016 Oct; 316(15):1555-1564. PubMed ID: 27706483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial Antifungal Strategy Reduces Mortality in Critically Ill Patients With Candidemia: A Propensity Score-Adjusted Analysis of a Multicenter Study.
    Garnacho-Montero J; Díaz-Martín A; Cantón-Bulnes L; Ramírez P; Sierra R; Arias-Verdú D; Rodríguez-Delgado M; Loza-Vázquez A; Rodriguez-Gomez J; Gordón M; Estella Á; García-Garmendia JL
    Crit Care Med; 2018 Mar; 46(3):384-393. PubMed ID: 29189345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
    Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
    BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.